Home›People›Andre Turenne
Andre Turenne

Andre Turenne

President and chief executive officer at Matchpoint Therapeutics

ExecutiveDirector
Updated Nov 20, 2026·Latest SEC filing Nov 20, 2026·Suggest an edit

About Andre Turenne

Andre Turenne is president and chief executive officer of Matchpoint Therapeutics. The company develops oral medicines for autoimmune and inflammatory diseases. He has advised Atlas Venture since 2021.

His pharmaceutical career spans more than 20 years. Before Matchpoint, Turenne was president and chief executive officer of Voyager Therapeutics. At Sanofi, he was senior vice president and global head of business development and licensing. His work covered transactions across therapeutic areas, drug types, and regions. His team completed more than 50 deals. He previously ran commercial operations for Genzyme’s renal franchise. He earned a bachelor’s degree from Kalamazoo College and an MBA from Dartmouth’s Tuck School of Business. He is also a Matchpoint director. He serves as an independent administrator at Inventiva.

Experience

This experience comes from official bios, from Andre Turenne's profile and from SEC filings. For roles taken from filings, the years are when the filings name Andre Turenne in the role, so the role may have started earlier or lasted longer.

Matchpoint Therapeutics Inc. Current
Director; President & Chief Executive Officer
2022 – Present · Watertown, MA
Matchpoint develops oral drugs that bind hard-to-treat protein targets in immune diseases.
Atlas Venture Current
Advisor
2021 – Present
Inventiva Current
Independent Administrator
Sanofi
Senior Vice President and Global Head of Business Development & Licensing
Managing Director, Australia and New Zealand (2015)
2015
Genzyme
Global Head of Commercial Operations for the renal franchise
Head, Strategy & Business Development (2012 – 2014)
2012 – 2014
Voyager Therapeutics
President and Chief Executive Officer

Key Colleagues at Startups

The people Andre Turenne works with at each company, as listed on that company's latest Form D.

Matchpoint Therapeutics Inc. · Form D, Nov 20, 2026
BM
Brian Matesic
Director; Principal, Norwest
KP
Kanishka Pothula
Director; Managing Partner, Nextech
JH
Jason Hafler
Director; Managing Director, Sanofi Ventures
BB
Bruce Booth
Chairman; Partner, Atlas Venture
DB
Daniel Becker
Director; Managing Director, Access Biotechnology
DN
Jared Cumming
Jared Cumming
Chief Scientific Officer
John O'Malley
John O'Malley
Chief Medical Officer

Sources

  1. SECMatchpoint Therapeutics Inc. Form D, filed Nov 20, 2026
  2. P2Matchpoint Therapeutics leadership appointment release